Acinetobacter: Introduction, Morphology, Pathogenicity, Lab Diagnosis, Treatment, Prevention, and Keynotes

Introduction

Acinetobacter is a genus of Gram-negative bacteria that are commonly found in the environment, including soil, water, and healthcare settings. While some species of Acinetobacter are harmless and part of the normal flora on human skin, others can cause opportunistic infections, particularly in healthcare-associated settings. Here are some key points about Acinetobacter:

  1. Classification: They belongs to the family Moraxellaceae and the order Pseudomonadales. The genus includes various species, with Acinetobacter baumannii being the most clinically significant and commonly studied species.
  2. Pathogenicity: A. baumannii, in particular, is known for its ability to cause infections in hospitalized patients with compromised immune systems, including bloodstream infections, pneumonia, urinary tract infections, and surgical site infections. It can also colonize medical devices, such as catheters or ventilators, leading to device-associated infections.
  3. Antibiotic Resistance: A. baumannii has gained attention due to its increasing resistance to multiple antibiotics, including carbapenems, which are often considered last-resort antibiotics. This multidrug-resistant nature makes Acinetobacter infections challenging to treat, leading to limited treatment options and higher mortality rates in some cases.
  4. Transmission: They can spread through person-to-person contact, contaminated surfaces, or healthcare equipment. It can survive on surfaces for extended periods, contributing to its ability to cause outbreaks in healthcare facilities.
  5. Risk Factors: Individuals at higher risk of Acinetobacter infections include those with weakened immune systems, prolonged hospital stays, invasive medical procedures, previous antibiotic exposure, or underlying health conditions.
  6. Diagnosis: Diagnosis of these infections is typically done through cultures of clinical specimens, such as blood, respiratory secretions, urine, or wound samples. Identification of the specific Acinetobacter species and antibiotic susceptibility testing are important for appropriate treatment selection.
  7. Prevention and Control: Preventive measures to reduce Acinetobacter infections include strict adherence to infection control practices, such as hand hygiene, proper disinfection of surfaces and medical equipment, surveillance of healthcare-associated infections, and prudent use of antibiotics.
  8. Treatment: Management of infections can be challenging due to antibiotic resistance. Treatment typically involves using antibiotics that have shown activity against the specific Acinetobacter strain, guided by susceptibility testing. In some cases, combination therapy may be necessary.
  9. Research and Surveillance: Due to the significant clinical impact of Acinetobacter infections, ongoing research is focused on understanding the mechanisms of antibiotic resistance, transmission dynamics, and developing new treatment strategies.

Morphology

Acinetobacter bacteria are Gram-negative, non-motile, non-spore-forming rods. Here are some key points regarding the morphology:

Acinetobacter: Introduction, Morphology, Pathogenicity, Lab Diagnosis, Treatment, Prevention, and Keynotes
Fig. Colony Morphology of Acinetobacter species on MacConkey agar
  1. Shape: They are typically described as coccobacilli, which means they are oval-shaped or slightly elongated rods.
  2. Size: The size of their cells can vary, but they are generally small, measuring about 1-2 micrometers in width and 1-3 micrometers in length.
  3. Cell Arrangement: Their cells usually occur singly or in pairs. They can also form short chains or clusters, but they do not typically exhibit extensive branching or filamentous growth.
  4. Capsule: Some strains of Acinetobacter, such as A. baumannii, have the ability to produce a polysaccharide capsule. This capsule can contribute to the virulence and antibiotic resistance of the bacterium.
  5. Flagella and Motility: Acinetobacter species are generally non-motile, meaning they do not possess flagella or exhibit active movement. However, some strains may have flagella-like structures that do not contribute to motility.
  6. Spore Formation: They are non-spore-forming, which means they do not produce endospores as a means of survival or reproduction.
  7. Gram Staining: Their cells are classified as Gram-negative bacteria due to their thin peptidoglycan layer in the cell wall. They typically stain pink or red in the Gram staining procedure.
Acinetobacter in Gram staining of culture microscopy at a magnification of 4000X
Fig. Acinetobacter in Gram staining of culture microscopy at a magnification of 4000X

Pathogenicity

They are opportunistic pathogens, meaning they primarily cause infections in individuals with compromised immune systems or those with underlying health conditions. While some species of Acinetobacter are considered commensal and are part of the normal flora on human skin, others, particularly A. baumannii, have emerged as significant healthcare-associated pathogens. Here are some key points regarding the pathogenicity of Acinetobacter:

  1. Healthcare-Associated Infections: A. baumannii is a leading cause of healthcare-associated infections, particularly in intensive care units (ICUs) and other healthcare settings. It can cause various types of infections, including bloodstream infections, pneumonia, urinary tract infections, wound infections, and surgical site infections.
  2. Antibiotic Resistance: A. baumannii is known for its ability to acquire resistance to multiple antibiotics, including carbapenems, which are often considered the last-resort antibiotics for many bacterial infections. This multidrug-resistant nature makes Acinetobacter infections challenging to treat, leading to limited treatment options and increased mortality rates in some cases.
  3. Biofilm Formation: A. baumannii has the ability to form biofilms, which are structured communities of bacteria encased in a matrix of extracellular polymeric substances. Biofilms provide protection to bacteria from the immune system and antimicrobial agents, making infections difficult to eradicate.
  4. Virulence Factors: A. baumannii possesses various virulence factors that contribute to its pathogenicity. These include outer membrane proteins, lipopolysaccharides, fimbriae, pili, capsule formation, and production of enzymes, such as beta-lactamases, that can inactivate antibiotics.
  5. Colonization and Environmental Persistence: Acinetobacter can persist in the hospital environment, surviving on various surfaces and medical equipment. It can colonize the skin, respiratory tract, and other sites in patients, increasing the risk of infection and transmission to others.
  6. Risk Factors: Individuals at higher risk of Acinetobacter infections include those with weakened immune systems, prolonged hospital stays, invasive medical procedures, previous antibiotic exposure, and those in critical care settings. Combat soldiers wounded in battlefield conditions are also at increased risk of Acinetobacter infections.
  7. Person-to-Person Transmission: They can be transmitted through direct contact with contaminated surfaces, healthcare personnel, or by the hands of infected individuals. Outbreaks of Acinetobacter infections have been reported in healthcare facilities, highlighting the potential for person-to-person transmission.
  8. Community-Acquired Infections: While less common, Acinetobacter infections can also occur in community settings, particularly in individuals with underlying health conditions or recent healthcare exposure.
Another footage of Acinetobacter in Gram staining of culture microscopy at a magnification of 4000X
Fig. Another footage of Acinetobacter in Gram staining of culture microscopy at a magnification of 4000X

Lab Diagnosis

The laboratory diagnosis of Acinetobacter infections involves several methods to identify and confirm the presence of Acinetobacter. Here are some key points on the lab diagnosis of Acinetobacter:

Acinetobacter baumannii in Gram staining of Culture Microscopy showing Gram negative cocc in singles, pairs, and Gram negative rods
Fig. Acinetobacter baumannii in Gram staining of Culture Microscopy showing Gram negative cocc in singles, pairs, and Gram negative rods
  1. Specimen Collection: Specimens commonly collected for the diagnosis of Acinetobacter infections include blood, respiratory secretions (sputum, tracheal aspirates), urine, wound swabs, and other relevant clinical samples. Proper collection techniques and aseptic measures should be followed to minimize contamination.
  2. Gram Stain: Gram staining is often the first step in the laboratory diagnosis of Acinetobacter infections. They appear as Gram-negative coccobacilli, typically occurring singly or in pairs.
  3. Culture: Clinical specimens are streaked onto appropriate culture media, such as blood agar or MacConkey agar. Acinetobacter species usually grow well on routine culture media within 24 to 48 hours. They often appear as smooth, non-hemolytic colonies.
  4. Biochemical Tests: Various biochemical tests are performed to identify Acinetobacter species. These tests may include oxidase test, catalase test, glucose fermentation, indole production, urease production, and others, depending on the specific identification methods used in the laboratory.
  5. Automated Identification Systems: Automated systems, such as Vitek, MALDI-TOF mass spectrometry, or other commercially available identification systems, can be employed to accurately identify Acinetobacter species based on their biochemical profiles.
  6. Antimicrobial Susceptibility Testing: Acinetobacter isolates should undergo antimicrobial susceptibility testing to determine their resistance patterns. Due to the increasing prevalence of multidrug-resistant Acinetobacter strains, it is crucial to test for susceptibility to multiple antibiotics.
  7. Molecular Methods: Molecular techniques, such as polymerase chain reaction (PCR) or sequencing of specific target genes, can be used for species identification and detection of antimicrobial resistance genes in Acinetobacter isolates.
  8. Epidemiological Investigations: Molecular typing methods, such as pulsed-field gel electrophoresis (PFGE), multilocus sequence typing (MLST), or whole-genome sequencing (WGS), may be used to investigate outbreaks or to determine the relatedness of Acinetobacter isolates.
Biocemical Tests of Acinetobacter baumannii-calcoaceticus complex (ABC)
Fig. Biocemical Tests of Acinetobacter baumannii-calcoaceticus complex (ABC)

Treatment

The treatment of Acinetobacter infections can be challenging due to the increasing prevalence of multidrug-resistant strains. The choice of treatment depends on various factors, including the site and severity of infection, antimicrobial susceptibility patterns, and patient-specific factors. Here are some key points regarding the treatment of Acinetobacter infections:

  1. Antimicrobial Susceptibility Testing: Acinetobacter isolates should undergo antimicrobial susceptibility testing to determine their resistance patterns. This helps guide treatment decisions and select appropriate antibiotics.
  2. Empirical Therapy: In severe infections or cases where susceptibility results are not immediately available, empirical therapy may be initiated based on local resistance patterns and institutional guidelines. Combination therapy with two or more antibiotics may be considered to improve efficacy.
  3. Antibiotic Options: A. baumannii is often resistant to many commonly used antibiotics, including penicillins, cephalosporins, and fluoroquinolones. Treatment options may include antibiotics such as carbapenems (e.g., meropenem, imipenem), polymyxins (e.g., colistin), tigecycline, and sulbactam.
  4. Combination Therapy: In severe infections or when dealing with multidrug-resistant strains, combination therapy with two or more antibiotics may be used to enhance the chances of success. The choice of combination therapy depends on the local susceptibility patterns and individual patient factors.
  5. Duration of Therapy: The duration of treatment varies depending on the site and severity of infection. In general, treatment is continued for a sufficient duration to ensure complete eradication of the infection.
  6. Consult Infectious Disease Specialist: In complex cases, involving multidrug-resistant strains or difficult-to-treat infections, it is advisable to consult with an infectious disease specialist for expert guidance in treatment decisions.
  7. Infection Control Measures: Strict adherence to infection control measures, such as hand hygiene, contact precautions, and appropriate disinfection of equipment and surfaces, is essential to prevent the spread of Acinetobacter infections within healthcare settings.
Antimicrobial susceptibility testing (AST) of Acinetobacter species on Muller-Hinton agar (MHA)
Fig. Antimicrobial susceptibility testing (AST) of Acinetobacter species on Muller-Hinton agar (MHA)

Prevention

Preventing Acinetobacter infections requires a multifaceted approach that includes infection control measures, antimicrobial stewardship, and surveillance. Here are key points on the prevention of Acinetobacter infections:

  1. Infection Control Practices: Implement and adhere to strict infection control practices in healthcare settings, including hospitals, clinics, and long-term care facilities. This includes:
    • Hand Hygiene: Promote and enforce proper hand hygiene practices among healthcare workers, patients, and visitors. Use soap and water or an alcohol-based hand sanitizer.
    • Personal Protective Equipment (PPE): Ensure appropriate use of PPE, such as gloves and gowns, when caring for patients with known or suspected these infections.
    • Environmental Cleaning: Maintain a clean healthcare environment through regular cleaning and disinfection of surfaces and equipment. Use appropriate disinfectants effective against Acinetobacter.
    • Contact Precautions: Implement and enforce contact precautions for patients with known or suspected Acinetobacter infections. This includes dedicated patient equipment and proper handling of contaminated materials.
  2. Antimicrobial Stewardship: Promote and follow antimicrobial stewardship principles to prevent the emergence and spread of drug-resistant Acinetobacter strains. This includes:
    • Rational Antibiotic Use: Prescribe antibiotics judiciously, following evidence-based guidelines and considering local susceptibility patterns. Avoid unnecessary antibiotic use, prolonged courses, and inappropriate selection.
    • Combination Therapy: Consider combination therapy when appropriate to improve treatment efficacy and reduce the risk of resistance development.
    • De-escalation of Therapy: Review and reassess antibiotic therapy regularly to optimize the choice and duration of treatment based on culture results and clinical response.
  3. Surveillance and Outbreak Investigation: Implement surveillance systems to monitor and detect theses infections. Perform active surveillance cultures, especially in high-risk areas or when there is an outbreak. Investigate and respond promptly to suspected outbreaks.
  4. Patient and Staff Education: Educate patients, healthcare workers, and visitors about Acinetobacter infections, prevention strategies, and the importance of adherence to infection control measures.
  5. Device-Associated Infections: Follow proper insertion and maintenance techniques for invasive medical devices, such as central venous catheters, urinary catheters, and ventilators, to reduce the risk of Acinetobacter colonization and infection.
  6. Environmental Measures: Implement measures to minimize environmental contamination, including proper cleaning and disinfection of shared equipment, such as respiratory devices and thermometers.
  7. Collaboration and Communication: Foster collaboration and communication between healthcare facilities to share information about Acinetobacter outbreaks, resistance patterns, and prevention strategies.

Keynotes

Here are some keynotes on Acinetobacter:

  1. Acinetobacter is a genus of Gram-negative bacteria that includes various species, with A. baumannii being the most clinically significant.
  2. A. baumannii has emerged as a significant healthcare-associated pathogen, causing various infections, particularly in immunocompromised patients and those in healthcare settings.
  3. These infections are often associated with multidrug resistance, making treatment challenging and increasing the risk of treatment failure.
  4. They have the ability to form biofilms, which contribute to its persistence on surfaces and resistance to antibiotics and disinfectants.
  5. They can cause a range of infections, including bloodstream infections, pneumonia, urinary tract infections, wound infections, and surgical site infections.
  6. The spread of Acinetobacter can occur through person-to-person transmission, contaminated surfaces, medical equipment, or healthcare personnel.
  7. Infection control measures, such as strict hand hygiene, appropriate use of personal protective equipment, and environmental cleaning, are crucial in preventing the spread of Acinetobacter infections in healthcare settings.
  8. Antimicrobial stewardship programs are essential to combat the emergence and spread of drug-resistant Acinetobacter strains.
  9. Timely and accurate laboratory diagnosis, including antimicrobial susceptibility testing, is important for guiding appropriate treatment.
  10. Prevention strategies for Acinetobacter infections involve a comprehensive approach, including infection control practices, antimicrobial stewardship, surveillance, and patient and staff education

Further Readings

  1. “Acinetobacter Infections: Epidemiology, Pathophysiology, and Management” – Article published in Clinical Microbiology Reviews, providing a comprehensive review of their infections, including their epidemiology, pathophysiology, and management strategies. (Source: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4576058/)
  2. “Acinetobacter baumannii: An Emerging Multidrug-Resistant Threat” – Review article discussing the emerging threat of multidrug-resistant Acinetobacter baumannii, its mechanisms of resistance, and potential treatment strategies. (Source: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6165123/)
  3. “Acinetobacter Infections and Treatment Options” – Review article summarizing the clinical characteristics of these infections, treatment options, and emerging therapies. (Source: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7165245/)
  4. “Acinetobacter baumannii: Evolution of Antimicrobial Resistance—Treatment Options” – Comprehensive review highlighting the evolving antimicrobial resistance in Acinetobacter baumannii and discussing treatment options and future perspectives. (Source: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6259121/)
  5. “Acinetobacter baumannii Infections: Epidemiology, Pathogenesis, and Treatment Options” – Review article providing an overview of the epidemiology, pathogenesis, and treatment options for Acinetobacter baumannii infections. (Source: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6198273/)

Leave a Comment